Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering
30 Janvier 2024 - 3:08PM
Business Wire
Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the
“Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical
company focused on developing life-changing therapies for allergic
and immunological diseases, today announced the pricing of an
underwritten offering of 10,340,000 shares of its common stock.
Each share of common stock is being sold at a price of $12.09. The
aggregate gross proceeds of the offering are expected to be
approximately $125 million, before deducting underwriting discounts
and commissions and other estimated offering expenses.
All of the securities are being offered by Astria. The offering
is expected to close on or about February 1, 2024, subject to
satisfaction of customary closing conditions.
The financing was led by RA Capital Management, with
participation from Perceptive Advisors, Venrock Healthcare Capital
Partners, TCGX, Driehaus Capital Management and Adage Capital
Partners L.P., in addition to other existing shareholders.
Jefferies and Evercore ISI are acting as joint book-running
managers for the offering. LifeSci Capital is acting as lead
manager.
The securities described above are being offered pursuant to a
shelf registration statement on Form S-3 (File No. 333-276057),
which was declared effective by the Securities and Exchange
Commission (the “SEC”) on December 29, 2023. The offering is being
made only by means of a prospectus supplement and the accompanying
prospectus. A final prospectus supplement relating to the offering
will be filed with the SEC and will be available at www.sec.gov.
When available, copies of the final prospectus supplement and the
accompanying prospectus may be obtained for free by contacting
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, New York, NY 10022, by telephone at (877)
821-7388, or by email at Prospectus_Department@Jefferies.com; or
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East
52nd Street, 35th Floor, New York, NY 10055, or by telephone at
(888) 474-0200, or by email at ecm.prospectus@evercore.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such jurisdiction.
About Astria Therapeutics
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by allergic and immunological diseases. Our lead
program, STAR-0215, is a monoclonal antibody inhibitor of plasma
kallikrein in clinical development for the treatment of hereditary
angioedema. STAR-0310 is a monoclonal antibody OX40 antagonist in
preclinical development for the treatment of atopic dermatitis.
Cautionary Note Regarding Forward Looking Statements
Any statements in this press release about future expectations,
plans and prospects for the Company, including statements about the
anticipated completion of the offering and the expected gross
proceeds of the offering, among other things, and statements
containing the words “believes,” “anticipates,” “plans,” “expects,”
“may” and similar expressions, constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: risks and uncertainties associated
with market conditions, the satisfaction of customary closing
conditions relating to the offering, as well as uncertainties
inherent in the initiation and completion of preclinical studies
and clinical trials and clinical development of the Company’s
product candidates; whether interim results from a clinical trial
will be predictive of the final results of the trial or the results
of future trials; expectations for regulatory approvals to conduct
trials or to market products; availability of funding sufficient
for the Company’s foreseeable and unforeseeable operating expenses
and capital expenditure requirements; other matters that could
affect the availability or commercial potential of the Company’s
product candidates; and general economic and market conditions and
other factors discussed in the “Risk Factors” section of the
Company’s Quarterly Report on Form 10-Q for the quarter ended
September 30, 2023, which is on file with the SEC, and in other
filings that the Company has made and may make with the SEC in the
future. In addition, the forward-looking statements included in
this press release represent the Company’s views as of the date of
this press release. The Company anticipates that subsequent events
and developments will cause the Company’s views to change. However,
while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing the Company’s views as of
any date subsequent to the date of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240130417221/en/
Investor Relations and Media: Elizabeth Higgins
investors@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Astria Therapeutics (NASDAQ:ATXS)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024